Literature DB >> 26518555

Changes in plasma catecholamines levels as preclinical biomarkers in experimental models of Parkinson's disease.

A R Kim1, M V Ugryumov2.   

Abstract

The goal of this study was to investigate the changes in the concentrations of blood plasma catecholamines as possible biomarkers of Parkinson's disease (PD) in the mouse experimental model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). A significant decrease was detected in the levels of dopamine and L-DOPA in the PD preclinical stage model as a result of the catecholamines systemic metabolism disfunction. In the PD early clinical stage models, the level of L-DOPA and dihydroxyphenylacetic acid decreased, which is consistent with the results of blood tests in untreated patients.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26518555     DOI： 10.1134/S1607672915050105

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


  12 in total

1.  Significance and origin of DOPA, DOPAC, and dopamine-sulphate in plasma, tissues and cerebrospinal fluid.

Authors:  Ebbe Eldrup
Journal:  Dan Med Bull       Date:  2004-02

2.  Protocol for the MPTP mouse model of Parkinson's disease.

Authors:  Vernice Jackson-Lewis; Serge Przedborski
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

Review 3.  Peripheral nervous system involvement in Parkinson's disease: evidence and controversies.

Authors:  C Comi; L Magistrelli; G D Oggioni; M Carecchio; T Fleetwood; R Cantello; F Mancini; A Antonini
Journal:  Parkinsonism Relat Disord       Date:  2014-10-18       Impact factor: 4.891

4.  Adrenomedullary secretion of DOPA, catecholamines, catechol metabolites, and neuropeptides.

Authors:  S L Chritton; S L Chinnow; C Grabau; M K Dousa; D Lucas; D Roddy; T L Yaksh; G M Tyce
Journal:  J Neurochem       Date:  1997-12       Impact factor: 5.372

Review 5.  Dysautonomia in Parkinson disease.

Authors:  David S Goldstein
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

6.  Modeling of presymptomatic and symptomatic stages of parkinsonism in mice.

Authors:  M V Ugrumov; V G Khaindrava; E A Kozina; V G Kucheryanu; E V Bocharov; G N Kryzhanovsky; V S Kudrin; V B Narkevich; P M Klodt; K S Rayevsky; T S Pronina
Journal:  Neuroscience       Date:  2011-03-05       Impact factor: 3.590

7.  TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice.

Authors:  Chaohui Zhao; Zaodung Ling; Mary B Newman; Ankush Bhatia; Paul M Carvey
Journal:  Neurobiol Dis       Date:  2007-01-17       Impact factor: 5.996

Review 8.  Sources and significance of plasma levels of catechols and their metabolites in humans.

Authors:  David S Goldstein; Graeme Eisenhofer; Irwin J Kopin
Journal:  J Pharmacol Exp Ther       Date:  2003-03-20       Impact factor: 4.030

9.  Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease.

Authors:  H Checkoway; L G Costa; J S Woods; A F Castoldi; B O Lund; P D Swanson
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1992

10.  Adrenal medulla and Parkinson's disease.

Authors:  S L Stoddard; G J Merkel; J A Cook; A R Zinsmeister; S W Carmichael
Journal:  Microsc Res Tech       Date:  1994-10-01       Impact factor: 2.769
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.